Navigation Links
Satori Pharmaceuticals to Present Data Highlighting Promise of Gamma-Secretase Modulators in Treatment of Alzheimer's Disease

CAMBRIDGE, Mass., July 10, 2012 /PRNewswire/ -- Satori™ Pharmaceuticals, a company dedicated to developing life-changing therapeutics for Alzheimer's disease (AD), today reported that three abstracts related to the use of gamma-secretase modulators (GSM) in the treatment of AD will be presented at the Alzheimer's Association International Conference (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia.

"These studies add to the growing body of evidence that suggests gamma-secretase modulators are unique compounds that have great potential to be promising new therapies for the treatment of Alzheimer's disease," said Jeff Ives, Ph.D., CEO and Board Member of Satori Pharmaceuticals. "We look forward to sharing our data at AAIC."

Details of Satori's presentations are as follows:

Oral Presentation Title:  Satori gamma-secretase modulators are efficacious in wild type rodents following either acute or steady-state dosing   Session Date and Time:  Sunday, July 15, 2012, 3:30 to 5 p.m.   Presentation Number:  O1-11-01

Poster Sessions  Title:  An improved cell-based method for determining the gamma-secretase enzyme activity against both NOTCH and APP substrates  Session Date and Time:  Monday, July 16, 2012, 1 to 3 p.m.   Presentation Number:  P2-095

Title: Pharmacokinetic properties of a Satori gamma-secretase modulator, SPI-1865, in multiple animal model systems  Session Date and Time:  Wednesday, July 18, 2012, 1 to 3 p.m.   Presentation Number:  P4-199

Please note that, pursuant to AAIC's policy, the abstracts for these presentations cannot be disclosed until the officially scheduled date and time of presentation.

About Satori's Gamma-Secretase Modulators   Alzheimer's disease is characterized by the formation of amyloid beta plaques in the brain. Plaques are primarily composed of two main forms of amyloid beta: AB40 and AB42. Satori's program aims to reduce the amount of AB42 in the brain by modulating gamma-secretase, thus lowering brain amyloid, plaque formation and associated damage to normal neuronal function. Studies have demonstrated Satori's proprietary class of gamma-secretase modulators (GSMs) achieve a reduction in AB42 levels without altering total amyloid beta levels in cell lines and animal models of the disease.

About Satori™ Pharmaceuticals  Satori Pharmaceuticals is developing life-changing therapeutics for Alzheimer's disease. Driven by a world-class team of drug development veterans and advisors, Satori is advancing best-in-industry medicines that aim to slow or stop disease progression. Our drug candidates selectively modulate gamma secretase, the enzyme generating the neurotoxic peptides that form amyloid beta plaques – the signature of this debilitating disease. For more information, visit

SOURCE Satori Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
(Date:12/1/2015)... , December 1, 2015 ... Contraceptive Injectables, Topical Contraceptives, Male Condoms, Female ... Vaginal Rings, Contraceptive Diaphragms, Contraceptive Sponges, Non-Surgical ... Size, Share, Growth, Trends and Forecast 2014 ... Transparency Market Research (TMR).The report states that ...
(Date:12/1/2015)... 1, 2015  InCarda Therapeutics, Inc. (InCarda), a privately-held ... therapies for cardiovascular conditions via the inhalation route, today ... Australia . InCarda is planning to ... Australia in the first half of 2016. ... centers in Adelaide and Melbourne.  ...
(Date:12/1/2015)... 2015 ) ... Alert Systems/Personal Emergency Response System (PERS) Market by ... Forecas" report to their offering. --> ... the "Medical Alert Systems/Personal Emergency Response System ... Geography - Global Forecas" report to their ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville has ... the only hospital in the region providing what is known as the world’s ... patients were revealed recently at a medical conference and published in The New ...
(Date:12/1/2015)... TX (PRWEB) , ... December 01, 2015 , ... Dr. ... of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single ... of the best among the many elite aesthetic physicians honored by the industry publication. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments ... to decreases in utilization of hospital and nonhospital care, according to a recent study ... Benchmarks for Louisiana, 16th Edition , found medical payments per claim with more than ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the 1980s we have seen vast improvements in scientific research and discoveries, leading ... strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform ...
(Date:12/1/2015)... ... , ... It’s official: Tattoo taboo is a thing of the past. One ... (a whopping one in three aged 18 to 25 is inked). As tattoos transition ... ink. In fact, RealSelf , the world’s largest community for learning and sharing ...
Breaking Medicine News(10 mins):